HealthTIES results presentation


Published on

Published in: Technology, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

HealthTIES results presentation

  1. 1. The European Regional Agenda, Science and Innovation The HealthTIES answers HealthTIES is an EU funded Regions of Knowledge for health program we add
  2. 2. Content HealthTIES context - Regional innovative ecosystems - Health challenges in the 21st Century HealthTIES Regions of Knowledge project 2010 – 2013 - Approach - Midterm results - Outlook 2012-2013 we add
  3. 3. HealthTIES context we add
  4. 4. Science-Innovation roadmaps Lisbon-Agenda Europe 2020; Flagship Initiative Innovation Union Europe Finance perspective 2014-2024 European Research ManagementFrom project approach to program and region approachAll focussing on creating a competitive European Research Area we add
  5. 5. Common Strategic Framework Science for innovation (individual research group) Innovation for society (social demands) Innovation for competitiveness (industry) Focus, mass, social and economic impact we add
  6. 6. EU innovation weaknesses Underinvestment in our knowledge foundation Unsatisfactory framework conditions - access to finance - high IPR costs - slow standardisation - ineffective use of public procurement To much fragmentation and costly duplication Source: Europe 2020 we add
  7. 7. Contemporary healthcare Challenges and Opportunities How do we improve medical care so as to live longer, healthier lives? How do we provide affordable medical care for the individual and the society? Where do we find the trained people who will provide healthcare? How do we guarantee the quality and safety of our medical care? How can we use the “answers” to these questions to provide economic opportunities? we add
  8. 8. HealthTIES project we add
  9. 9. HealthTIES regions are Strong European regions in  Life science &  Medical technology Both  Scientific &  Industrial we add
  10. 10. The HealthTIES approach Modeling Joint Analysis Fact Finding Action SWOTVirtual Reference Region Plan Monitoring over years to come we add
  11. 11. Modeling the ecosystem – WP2 Research funding Innovation system Companies Spin off companiesKnowledge Jobs Business Development Input outputR&D Infrastructure Patents Products Human Capital Facilities / Infrastructure Capital we add
  12. 12. Data gathering of ecosystem – WP3 Approach Open sources for input and output “We all have pieces of the puzzle” Data needs to be reproducible Balance relevance vs accuracy we add
  13. 13. Data gathering ecosystem – WP3 parametersInput Innovation System OutputProfs H-factor >30 University spin-offs FTEs Biotech companiesPublications Granted US patents Biotech companies < and > 20 FTEsResearch funding WAIT indicator for countries Big trade salesInternat./nat. grad. MSc students Big public-private projects Products on marketInternat./nat. PhD students TTO FTEs Products clinical trialsJunior/senior ERC grants Nat. govern. innov. support Products discovery phaseResearch m2 Nat. attractiveness (WEF index) Medicines available in countriesResearch hosptial beds Science parks m2 Total/number investmentsClinical trials phase I and II Science parks support FTEs Average Series A investments we add
  14. 14. Benchmarking and best practices Based upon  key figures +  Visits to each others - scienceparks, - universities, - incubators etc. we add
  15. 15. Virtual Reference Region we add
  16. 16. Strengths Weaknesses Opportunities Threats Strengths Weaknesses Excellent research Small, fragmented environment bioscience parks Good numbers of ERC Low numbers of research grants and joint research students projects Few research hospital beds High investment levels and clinical trials Good numbers of granted US patents Opportunities Threats Improve innovation system Adverse economic Capitalise on US patents environments Increase start-ups and TTOs not maiximising their attract more companies effectiveness for all stakeholders Improve job opportunities Improve discovery and availability of medicines we add
  17. 17. Research and Development Strength - WP4 Science via Web of Knowledge & Network Industry via & Network we add
  18. 18. Outcomes WP4Benchmark Web of Knowledge strengths 12 detailed research group collections on matrix crossroads we add
  19. 19. Analysis and best practices result in regional and joint actions HealthTIES – X Joint actions EU regions in health innovation Regional actions Bench mark results Region 1 Region 2 Region 3 Region 4 Region 5 we add
  20. 20. Actions following from analyses Themes are1. Innovation ecosystem business development, incubator cooperation, investment fund, clinical trial portal2. Research, technology, development agenda disseminate gained insights, increase joint RTD projects, smart specialisation strategy, exchange of (teaching) staff etc.3. Dissemination, increasing the participation of others Keep involving our own regional stakeholders during JAP phase, promote the VRR during conferences, actively invite other regions to use it, keep improving the model we add
  21. 21. Joint Action Plan WP5/6 Structure example Barcelona Debrecen Medical Delta Oxford ZurichJoint Action 1 participant participant participant participant LeaderCombining clinical trialsJoint Action 2 participant participant participant leader ParticipantJoint R&D projectsRegional action 1 Already - Already Local AlreadySetup incubator present present. leader present. Advisor AdvisorRegional action 2 - Local leader Local leader advisor advisorIncrease ERC grants Joint Action Plan is under construction. Examples do not reflect the actual situation. we add
  22. 22. JAP realization - formatProject: [Title] Project coordinator: [Name + organisation]Description [Aim of the project + rationale (based upon analysis)]Result in 2013Others involved [names + organisations, from own region + from other HealthTIES regions if applicable]HealthTIES region [Region + name best practice]with Best PracticeApproach [Describe the main and visible actions results in period 2012-2013, the budget origin and involvement of experts etc.] we add
  23. 23. Backup we add
  24. 24. Industry in Medical Deltacurrent status in 300 companies 18.000 industrial jobs 140 products on market 85 in development we add
  25. 25. HealthTIES key PeopleDaily BoardHans Goossens (Province of South Holland, coordinator)Pancras Hogendoorn (LUMC, Scienctific director)Roel Kamerling (Medical Delta / TU Delft, managing directorLaura Vis (Province of South Holland, Secretary Daily Board)Executive Committee (= work package leaders + daily board)Nerea Alonso (BioCat)Bass Hassan and Laurel Edmunds (Oxford University)Ernst Hafen and Silvia Gluderer (ETH Zurich)Máté Rab and Brigitta Máté (Debrecen University)In consortium board for Medical DeltaHenri Lenferink (Mayor of Leiden)Huib Pols, dean of the Erasmus Medical Centre) we add
  26. 26. Input results WP3 we add
  27. 27. Input results WP3 we add
  28. 28. Innovation system results WP3 we add
  29. 29. Innovation system results WP3 we add
  30. 30. Output results WP3 we add
  31. 31. Output results WP3 we add
  32. 32. Biocat we add
  33. 33. Biocat Strengths Weaknesses High availability of Scarce phase 3/4 investm. scientific profiles in life Lack of financial support at sciences level of ideas Good programmes Duplication of equipment attracting foreign excellent scientist Insufficient big PPPs Important network of Weak valorisation research hospi. performing structure in hospitals clinical trials High density of incubators Opportunities Threats Public procurement for Intensified debate on innovations framework healthcare systems European programmess sustainability for boosting public-private Relocation of big pharma partnerships R&D structures Creation of new sectorial Difficulties to adapt to new VC funds market paradigms we add
  34. 34. Debrecen we add
  35. 35. Debrecen Strengths Weaknesses Governmental innovation Little research, incubator and support science park infrastructure Many clinical trials in phase Few big PPPs I and II Small qualified support staff Attractive region for Few biotech companies investors Few internat. renowned profs, Many full-time employees few internat. students Opportunities Threats Public procurement for Intensified debate on innovations framework healthcare systems European programmess for sustainability boosting public-private Relocation of big pharma partnerships R&D structures Creation of new sectorial Difficulties to adapt to new VC funds market paradigms we add
  36. 36. Medical Delta we add
  37. 37. Medical Delta we add
  38. 38. Oxford we add
  39. 39. Oxford we add
  40. 40. Zurich we add
  41. 41. Zurich we add
  42. 42. InputInnovation systemOutput Products we add
  43. 43. Worldwide context we add